What is Legend Biotech Corporation (LEGN)?

Legend Biotech Corporation (LEGN) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of LEGN?

The current price of LEGN is $21.56. Prices are updated in real time on Stocks360.

What is LEGN's price-to-earnings (PE) ratio?

LEGN's trailing twelve-month PE ratio is -43.12, based on current price and earnings per share data available on Stocks360.

What is LEGN's market capitalization?

LEGN's market capitalization is $3,987,375,047.00, placing it in the mid-cap tier.

Legend Biotech Corporation (LEGN)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$21.56

Market Cap

$3.99B

PE (TTM)

-43.12

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.40

Day Range

$19.94 – $21.67

52-wk Range

$16.24 – $37.50

Avg Volume

N/A

Volume

2.12M

Legend Biotech Corporation (LEGN) is a publicly traded company in the Healthcare sector. Latest price: $21.56. Market cap $3.99B. Trailing PE -43.12. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-28 · $32.57 2026-10-27 · $21.56 (-33.80%)

Earnings

Most Recent

Aug 11, 2026

EPS $0.09 vs est. $0.12

Missed by $0.03

Next Earnings

Nov 11, 2026

EPS estimate $0.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Legend Biotech Corporation

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting d…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-43.12×
P/S (TTM)	3.14×
P/B	3.28×
P/FCF (TTM)	-15.60×
EV / EBITDA	1747.40×
EV / Sales	2.83×
Earnings Yield	-2.27%
Free Cash Flow Yield	-6.41%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.59B
Revenue (TTM)	$1.27B
Net Income (TTM)	-$90.60M
Free Cash Flow (TTM)	-$207.61M
Net Debt	-$394.71M
Working Capital	$823.83M
Gross Margin	56.58%
Operating Margin	-4.42%
Net Margin	-7.21%
Return on Equity	-8.70%
Return on Invested Capital	-3.71%